MedTrace Logo

Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center

NCT02221661 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 606

Last updated 2014-08-22

No results posted yet for this study

Summary

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory complaint and/or cognitive impairments.

Conditions

Sponsors & Collaborators

  • Olivier SOL, MD

    collaborator UNKNOWN

  • Diaxonhit

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221661 on ClinicalTrials.gov